918348-67-1 Usage
Uses
Used in Pharmaceutical Industry:
XL-652 is used as a raw material or intermediate for the production of pharmaceuticals due to its high purity and stability, which are essential for the development of effective and safe medications.
Used in Dye Industry:
XL-652 is utilized as a key component in the manufacturing of dyes, contributing to the creation of vibrant and long-lasting colorants for various applications.
Used in Chemical Products Industry:
XL-652 serves as a valuable intermediate in the production of a wide range of chemical products, enhancing their quality and performance.
It is crucial to handle XL-652 with care and implement proper safety measures during its use in any industry to ensure the safety of workers and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 918348-67-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,8,3,4 and 8 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 918348-67:
(8*9)+(7*1)+(6*8)+(5*3)+(4*4)+(3*8)+(2*6)+(1*7)=201
201 % 10 = 1
So 918348-67-1 is a valid CAS Registry Number.
918348-67-1Relevant articles and documents
Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRβ
Kick, Ellen,Martin, Richard,Xie, Yinong,Flatt, Brenton,Schweiger, Edwin,Wang, Tie-Lin,Busch, Brett,Nyman, Michael,Gu, Xiao-Hui,Yan, Grace,Wagner, Brandee,Nanao, Max,Nguyen, Lam,Stout, Thomas,Plonowski, Artur,Schulman, Ira,Ostrowski, Jacek,Kirchgessner, Todd,Wexler, Ruth,Mohan, Raju
, p. 372 - 377 (2015)
A series of biaryl pyrazole and imidazole Liver X Receptor (LXR) partial agonists has been synthesized displaying LXRβ selectivity. The LXRβ selective partial agonist 18 was identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50 = 1.2 μM, 55% efficacy). In mice 18 displayed peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist.
